Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADORE: Oral Edaravone (FAB122) in ALS
NCT05178810Phase 3Completed
- Sponsor
- Ferrer
- Start
- Oct 2021
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing FAB122 with Placebo (2 arms). Primary endpoint: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised at 48 weeks. Started Oct 2021; status: completed.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05178810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178810.